Intravenous adenosine and lidocaine in patients with acute myocardial infarction. 1998

K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn. 55905, USA.

OBJECTIVE A pilot study was designed to assess the safety of combined intravenous adenosine and lidocaine in patients with acute myocardial infarction and to estimate the likelihood of a beneficial effect on final infarct size. BACKGROUND Adenosine plus lidocaine reduces infarct size in animals, but the safety and efficacy in human beings is unknown. RESULTS Adenosine (70 microg/kg per minute intravenous infusion) plus lidocaine (1 mg/kg intravenous bolus injection and 2 mg/kg per minute infusion) was given to 45 patients with acute myocardial infarction. Patients underwent immediate balloon angioplasty without preceding thrombolytic therapy. Myocardial perfusion defects were measured with serial technetium 99m sestamibi studies. One patient developed persisting hypotension in conjunction with a large inferolateral myocardial infarction. Transient hypotension in three other patients resolved with a reduction in adenosine. Advanced atrioventricular block was never observed. Other adverse events (including atrial fibrillation, ventricular tachyarrhythmia, bradycardia, and respiratory distress) occurred at low frequencies, as expected for patients with acute myocardial infarction. An initial median perfusion defect of 45% of the left ventricle (60% for anterior infarction, 17% for nonanterior infarction) was observed. At hospital discharge (mean +/- SD = 4.3 +/- 2.1 days) the median value was 12%, and at 8 +/- 4 weeks it was 3% (7% for anterior infarction, 0% for nonanterior infarction); 14 patients had no measurable follow-up. Compared with historical control patients, prehospital discharge measurements were not different but late perfusion defects were improved. CONCLUSIONS Treatment with intravenous adenosine and lidocaine during acute myocardial infarction has sufficient safety and potential for improved myocardial salvage. Randomized studies are justified.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008012 Lidocaine A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE. Lignocaine,2-(Diethylamino)-N-(2,6-Dimethylphenyl)Acetamide,2-2EtN-2MePhAcN,Dalcaine,Lidocaine Carbonate,Lidocaine Carbonate (2:1),Lidocaine Hydrocarbonate,Lidocaine Hydrochloride,Lidocaine Monoacetate,Lidocaine Monohydrochloride,Lidocaine Monohydrochloride, Monohydrate,Lidocaine Sulfate (1:1),Octocaine,Xylesthesin,Xylocaine,Xylocitin,Xyloneural
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
March 1985, Giornale italiano di cardiologia,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
March 1973, Pennsylvania medicine,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
October 1968, American heart journal,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
May 1977, Harefuah,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
April 1985, Clinical pharmacology and therapeutics,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
November 1978, Medicine,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
January 1991, Henry Ford Hospital medical journal,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
February 1972, JAMA,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
February 2022, The American journal of the medical sciences,
K N Garratt, and D R Holmes, and V Molina-Viamonte, and G S Reeder, and D O Hodge, and K R Bailey, and J K Lobl, and D A Laudon, and R J Gibbons
July 1991, Arquivos brasileiros de cardiologia,
Copied contents to your clipboard!